Ovarian Cancer
📧 Sign up to get email alerts when something new happens for Ovarian Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-09-17Clinical Trial Update: Stepping Into Survivorship: Harnessing Behavioral Economics to Improve Quality of Life in Ovarian Cancer [NA]
Trial investigating behavioral economics strategies to improve quality of life in ovarian cancer has completed and results posted.
-
CLINICAL_TRIALS trial_result · 2021-09-16Clinical Trial Update: Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer [Phase 1]
Phase 1 clinical trial update for a vaccine therapy in ovarian epithelial, primary peritoneal, or fallopian tube cancer with completed statu…
-
FDA approval · 2021-09-09FDA Approved: TALZENNA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for TALZENNA (talazoparib) submitted by Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2021-09-05Clinical Trial Update: Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer. [Phase 2]
Phase 2 trial evaluating decitabine plus carboplatin versus physician's choice chemotherapy for recurrent, platinum-resistant ovarian cancer…
-
CLINICAL_TRIALS trial_result · 2021-09-02Clinical Trial Update: Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]
Phase 2 study examining whether physical activity tracked by Fitbit Charge 2 improves quality of life in participants with recurrent ovarian…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-09-01Clinical Trial Update: Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer [Phase 2]
Phase 2 trial evaluating niraparib plus oral etoposide in platinum-resistant/refractory recurrent ovarian cancer; efficacy and safety data a…
-
CLINICAL_TRIALS trial_result · 2021-08-27Clinical Trial Update: Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment [Phase 3]
A Phase 3 trial comparing Niraparib-TSR-042 (Dostarlimab) to physician's choice chemotherapy in recurrent ovarian/fallopian tube/primary per…
-
CLINICAL_TRIALS trial_result · 2021-08-27Clinical Trial Update: Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination [Phase 1, Phase 2]
A phase 1/2 trial comparing carboplatin-paclitaxel-bevacizumab with alternative regimens including rucaparib, selected by HRD status, in adv…
-
CLINICAL_TRIALS trial_result · 2021-08-12Clinical Trial Update: Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer [Phase 1]
A Phase 1 clinical trial evaluating a monoclonal antibody therapy in patients with ovarian cancer scheduled for surgery was terminated; resu…
-
CLINICAL_TRIALS trial_result · 2021-08-10Clinical Trial Update: Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer [Phase 1, Phase 2]
Phase 1/2 trial evaluating atezolizumab in combination with neoadjuvant chemotherapy for newly diagnosed advanced-stage ovarian cancer has c…
-
CLINICAL_TRIALS trial_result · 2021-08-10Clinical Trial Update: A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH ) [Phase 2]
Phase 2 trial evaluating ATG 008 (dual mTORC1/2 inhibitor) or ATG-010 (selective exportin 1 inhibitor) in combination with chemotherapy for …
-
CLINICAL_TRIALS trial_result · 2021-08-09Clinical Trial Update: Reprab Study: PLD + Trabectedin Rechallenge [Phase 2]
Phase 2 trial update for PLD + Trabectedin rechallenge in relapsed ovarian cancer.
-
CLINICAL_TRIALS trial_result · 2021-08-09Clinical Trial Update: Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites [NA]
Clinical trial update for Canady Helios cold plasma scalpel at surgical margins and macroscopic tumor sites; status and results data are unc…
-
CLINICAL_TRIALS trial_result · 2021-08-05Clinical Trial Update: Analyzing the Composition of Tears to Identify Cancer [Phase 1, Phase 2]
Phase 1/2 trial exploring tear composition as a biomarker approach for cancer detection, involving breast and ovarian cancer cohorts.
-
CLINICAL_TRIALS trial_result · 2021-08-03Clinical Trial Update: Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer [Phase 2]
A Phase 2 trial evaluating pembrolizumab in combination with pegylated liposomal doxorubicin for recurrent platinum-resistant ovarian, fallo…
-
CLINICAL_TRIALS withdrawal · 2021-07-15Clinical Trial Update: Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer [Phase 3]
Phase 3 trial comparing Niraparib-bevacizumab-Dostarlimab vs Niraparib-bevacizumab to standard of care in recurrent ovarian cancer has been …
-
CLINICAL_TRIALS trial_result · 2021-07-13Clinical Trial Update: Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer [Phase 3]
A Phase 3 clinical trial evaluating optimal treatment with bevacizumab in patients with platinum-sensitive recurrent ovarian cancer has comp…
-
CLINICAL_TRIALS trial_result · 2021-07-13Clinical Trial Update: A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) [Phase 2]
Phase 2 study ARIEL2 evaluating rucaparib in platinum-sensitive relapsed high-grade ovarian/fallopian tube/primary peritoneal cancer complet…
-
CLINICAL_TRIALS trial_result · 2021-06-18Clinical Trial Update: To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer [Phase 4]
Phase 4 trial assessing olaparib maintenance monotherapy in BRCA or HRR+ mutated ovarian cancer; completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-06-16Clinical Trial Update: Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer [Phase 1]
Phase 1 trial evaluating intraperitoneal infusion of autologous monocytes with Sylatron (peginterferon alfa-2b) and Actimmune (interferon ga…
-
CLINICAL_TRIALS trial_result · 2021-06-14Clinical Trial Update: Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer [Phase 2]
Phase 2 clinical trial evaluating NKTR-102 in metastatic or locally advanced ovarian cancer has completed with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-06-03Clinical Trial Update: Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer [Phase 2]
Phase 2 trial updating dose-dense paclitaxel with pembrolizumab in platinum-resistant ovarian cancer has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-06-02Clinical Trial Update: A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer [Phase 3]
A Phase 3 trial evaluating ZL-2306 (niraparib) as maintenance therapy after first-line chemotherapy in advanced ovarian cancer.
-
CLINICAL_TRIALS trial_result · 2021-06-01Clinical Trial Update: A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors [Phase 2]
Phase 2 study of TQ-B3525 tablets in gynecologic tumors with PIK3CA/PIK3R1/2 alterations (advanced endometrial, cervical, and ovarian cancer…
-
CLINICAL_TRIALS trial_result · 2021-05-25Clinical Trial Update: SGI-110 in Combination With Carboplatin in Ovarian Cancer [Phase 2]
Results from a Phase 2 trial of SGI-110 (guadecitabine) plus carboplatin in ovarian cancer have been completed and posted.